PMID- 32901891
OWN - NLM
STAT- MEDLINE
DCOM- 20210719
LR  - 20210921
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Print)
IS  - 1021-335X (Linking)
VI  - 44
IP  - 5
DP  - 2020 Nov
TI  - Resveratrol inhibits viability and induces apoptosis in the small‑cell lung 
      cancer H446 cell line via the PI3K/Akt/c‑Myc pathway.
PG  - 1821-1830
LID - 10.3892/or.2020.7747 [doi]
AB  - There have been no major breakthroughs in the treatment of small‑cell lung cancer 
      (SCLC) in recent decades. It is thus essential to explore new or adjuvant 
      treatment options for SCLC. Resveratrol (Res) is a natural antioxidant revealed 
      to influence the entire process of cancer development. Accordingly, the present 
      study used the SCLC cell line H446 to explore the antitumor mechanism of Res. 
      Cells were treated with 40 microg/ml Res with or without pretreatment with the 
      antioxidant N‑acetyl‑L‑cysteine (NAC). H446 cell viability and apoptosis were 
      assessed with MTT and flow cytometry, and the expression of cytochrome c and the 
      PI3K/Akt/c‑Myc pathway and the nuclear translocation of apoptosis inducing factor 
      (AIF) were assessed by western blotting. In addition, the changes in ROS content 
      and mitochondrial membrane potential were determined. The results revealed that 
      Res inhibited H446 cell viability and induced apoptosis, increased cytochrome c 
      expression, inhibited the expression of PI3K/Akt/c‑Myc signaling pathway 
      components, and promoted the translocation of AIF from the cytoplasm to the 
      nucleus in H446 cells. However, NAC pretreatment reversed these changes to 
      various extents. The results of the present study indicated that Res may inhibit 
      the viability and promote the apoptosis of human SCLC H446 cells through the 
      PI3K/Akt/c‑Myc pathway and that oxidative stress and mitochondrial membrane 
      potential depolarization may be involved in the aforementioned processes.
FAU - Li, Wangping
AU  - Li W
AD  - Department of Pulmonary and Critical Care Medicine, Tangdu Hospital, Air Force 
      Military Medical University, Xi'an, Shaanxi 710038, P.R. China.
FAU - Li, Chunmei
AU  - Li C
AD  - Department of Pulmonary and Critical Care Medicine, Tangdu Hospital, Air Force 
      Military Medical University, Xi'an, Shaanxi 710038, P.R. China.
FAU - Ma, Lijie
AU  - Ma L
AD  - Department of Pulmonary and Critical Care Medicine, General Hospital of Western 
      Theater Command, Chengdu, Sichuan 610083, P.R. China.
FAU - Jin, Faguang
AU  - Jin F
AD  - Department of Pulmonary and Critical Care Medicine, Tangdu Hospital, Air Force 
      Military Medical University, Xi'an, Shaanxi 710038, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20200901
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Antioxidants)
RN  - 0 (Apoptosis Inducing Factor)
RN  - 0 (MYC protein, human)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (Reactive Oxygen Species)
RN  - 9007-43-6 (Cytochromes c)
RN  - EC 2.7.11.1 (AKT1 protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Antioxidants/pharmacology
MH  - Apoptosis/drug effects
MH  - Apoptosis Inducing Factor/metabolism
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Cytochromes c/metabolism
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/metabolism/pathology
MH  - Membrane Potential, Mitochondrial/drug effects
MH  - Phosphatidylinositol 3-Kinases/*metabolism
MH  - Proto-Oncogene Proteins c-akt/antagonists & inhibitors/*metabolism
MH  - Proto-Oncogene Proteins c-myc/antagonists & inhibitors/*metabolism
MH  - Reactive Oxygen Species/metabolism
MH  - Resveratrol/*pharmacology
MH  - Signal Transduction/drug effects
MH  - Small Cell Lung Carcinoma/*drug therapy/metabolism/pathology
PMC - PMC7550979
OTO - NOTNLM
OT  - resveratrol
OT  - small-cell lung cancer
OT  - PI3K/Akt/c-Myc pathways
EDAT- 2020/09/10 06:00
MHDA- 2021/07/20 06:00
PMCR- 2020/09/01
CRDT- 2020/09/09 08:47
PHST- 2019/11/20 00:00 [received]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2021/07/20 06:00 [medline]
PHST- 2020/09/09 08:47 [entrez]
PHST- 2020/09/01 00:00 [pmc-release]
AID - or-44-05-1821 [pii]
AID - 10.3892/or.2020.7747 [doi]
PST - ppublish
SO  - Oncol Rep. 2020 Nov;44(5):1821-1830. doi: 10.3892/or.2020.7747. Epub 2020 Sep 1.